TAG is organizing this webinar on July 29 for community organizations and advocates to raise awareness about the HCV Elimination bill, and prepare them to meet and engage with their Senators during the August recess in their district offices or Town Hall meetings.
TAG's Senior TB Project Associate, Erin McConnell, created this 'zine about TAG for Pride 2025. It's about fighting back, and goes over current threats, action items, and action steps on how to show up.
Treatment Action Group (TAG) is seeking a dynamic, highly motivated, and organized Grant Officer to support grant and fundraising efforts. This position will report to TAG's Chief Operating Officer.
Save the Date: Monday, October 20, 2025 , when our Research in Action Awards return this fall! We'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV). And until July 1, get tickets at our special-early bird rate!
This publication discusses findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for Hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid.
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
What does TAG's work look like in action? Here we step into a day in the life of our TB program co-directors, Mike Frick and Lindsay McKenna, to see how their advocacy for better TB research and policy — made possible by your support — are driving meaningful change to save lives and empower communities affected by TB.
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP).
People living with or at risk of hepatitis C Virus (HCV), health care providers, and policymakers in low- and middle-income countries (LMICs) showed significant interest in a potential long-acting HCV cure, recent surveys have found.